SPARC and lung cancer: Given the importance of ECM remodelling in cancer, Andriani and colleagues (2018) explored the biomarker potential of collagen type X alpha 1 (COL10A1), collagen type XI alpha 1 (COL11A1) and collagen-binding molecule, secreted protein acidic and rich in cysteine (SPARC) in plasma of lung cancer patients [198].